TY - JOUR
T1 - Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrett's esophagus
T2 - a propensity score−matched cohort study
AU - Agarwal, Siddharth
AU - Alshelleh, Mohammad
AU - Scott, Jamie
AU - Dhaliwal, Lovekirat
AU - Codipilly, D. Chamil
AU - Dierkhising, Ross
AU - Leggett, Cadman L.
AU - Wang, Kenneth K.
AU - Otaki, Fouad A.
AU - Trindade, Arvind J.
AU - Iyer, Prasad G.
N1 - Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: C. L. Leggett: Research support from Nine Point Medical. K. K. Wang: Research support from Medical: Research and Pentax Medical. A. J. Trindade: Consultant for Pentax Medical. P. G. Iyer: Research funding from Exact Sciences and Pentax Medical; consultant for Medtronic. All other authors disclosed no financial relationships. Research support for this study (P. Iyer) was provided by in part by the Freeman Foundation.
Publisher Copyright:
© 2022 American Society for Gastrointestinal Endoscopy
PY - 2022/3
Y1 - 2022/3
N2 - Background and Aims: Strong evidence supports the use of radiofrequency ablation (RFA) in the management of dysplastic/neoplastic Barrett's esophagus (BE). Recently, the efficacy of the cryoballoon ablation (CBA) system was demonstrated in multicenter cohort studies. We aimed to assess the comparative effectiveness and safety of these 2 ablation modalities for endoscopic eradication therapy (EET) in a cohort study. Methods: Data were abstracted on patients with dysplastic BE or intramucosal carcinoma undergoing EET using RFA or CBA as the primary ablation modality at 2 referral centers. The primary outcome was the rate of complete remission intestinal metaplasia (CRIM). Secondary outcomes were rates of complete remission of dysplasia (CRD) and adverse events. Cox proportional hazards models and propensity scored–matched analyses were conducted to compare outcomes. Results: Three hundred eleven patients (CBA, 85 patients; RFA, 226 patients) with a median follow-up of 1.5 years (interquartile range,.8, 2.5) in the RFA group and 2.0 years (interquartile range, 1.3, 2.5) in the CBA group were studied. On multivariable analyses, the chances of reaching CRD and CRIM were not influenced by ablation modality. Propensity score–matched analysis revealed a comparable chance of achieving CRIM (CBA vs RFA: hazard ratio, 1.24; 95% confidence interval,.79-1.96; P =.35) and CRD (CBA vs RFA: hazard ratio, 1.19; 95% confidence interval,.82-1.73; P =.36). The CBA group had a higher stricture rate compared with the RFA group (10.4% vs 4.4%, P =.04). Conclusions: Histologic outcomes of EET using CBA and RFA for dysplastic BE appear to be comparable. A randomized trial is needed to definitively compare outcomes between these 2 modalities.
AB - Background and Aims: Strong evidence supports the use of radiofrequency ablation (RFA) in the management of dysplastic/neoplastic Barrett's esophagus (BE). Recently, the efficacy of the cryoballoon ablation (CBA) system was demonstrated in multicenter cohort studies. We aimed to assess the comparative effectiveness and safety of these 2 ablation modalities for endoscopic eradication therapy (EET) in a cohort study. Methods: Data were abstracted on patients with dysplastic BE or intramucosal carcinoma undergoing EET using RFA or CBA as the primary ablation modality at 2 referral centers. The primary outcome was the rate of complete remission intestinal metaplasia (CRIM). Secondary outcomes were rates of complete remission of dysplasia (CRD) and adverse events. Cox proportional hazards models and propensity scored–matched analyses were conducted to compare outcomes. Results: Three hundred eleven patients (CBA, 85 patients; RFA, 226 patients) with a median follow-up of 1.5 years (interquartile range,.8, 2.5) in the RFA group and 2.0 years (interquartile range, 1.3, 2.5) in the CBA group were studied. On multivariable analyses, the chances of reaching CRD and CRIM were not influenced by ablation modality. Propensity score–matched analysis revealed a comparable chance of achieving CRIM (CBA vs RFA: hazard ratio, 1.24; 95% confidence interval,.79-1.96; P =.35) and CRD (CBA vs RFA: hazard ratio, 1.19; 95% confidence interval,.82-1.73; P =.36). The CBA group had a higher stricture rate compared with the RFA group (10.4% vs 4.4%, P =.04). Conclusions: Histologic outcomes of EET using CBA and RFA for dysplastic BE appear to be comparable. A randomized trial is needed to definitively compare outcomes between these 2 modalities.
UR - http://www.scopus.com/inward/record.url?scp=85119322722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119322722&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2021.09.037
DO - 10.1016/j.gie.2021.09.037
M3 - Article
C2 - 34624303
AN - SCOPUS:85119322722
SN - 0016-5107
VL - 95
SP - 422-431.e2
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 3
ER -